233 related articles for article (PubMed ID: 32436765)
1. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Peccianti C; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavo SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Stingeni L; Caruso C; Argenziano G;
J Dermatolog Treat; 2022 Mar; 33(2):1146-1149. PubMed ID: 32436765
[No Abstract] [Full Text] [Related]
2. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Gurioli C; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Esposito M; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e384-e388. PubMed ID: 36225088
[No Abstract] [Full Text] [Related]
3. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
[TBL] [Abstract][Full Text] [Related]
4. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
6. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
[TBL] [Abstract][Full Text] [Related]
8. Severe eczema in Wiskott-Aldrich syndrome-related disorder successfully treated with dupilumab.
Alzahrani F; Miller HK; Sacco K; Dupuy E
Pediatr Dermatol; 2024; 41(1):143-144. PubMed ID: 37469225
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis.
Marcant P; Balayé P; Merhi R; Jendoubi F; Nosbaum A; Raison-Peyron N; Du-Thanh A; Lasek A; Ferrier le Bouedec MC; Tetart F; Valois A; Barbarot S; Soria A; Jachiet M; Staumont-Sallé D;
J Eur Acad Dermatol Venereol; 2021 Jun; 35(6):e394-e396. PubMed ID: 33594731
[No Abstract] [Full Text] [Related]
10. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry.
Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
Contact Dermatitis; 2022 Aug; 87(2):185-191. PubMed ID: 35279856
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
[TBL] [Abstract][Full Text] [Related]
12. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
Guédon C; Tauber M; Linder C; Paul C; Shourick J
Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
[No Abstract] [Full Text] [Related]
13. A review of dupilumab in the treatment of atopic diseases.
Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
[TBL] [Abstract][Full Text] [Related]
14. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
15. A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab.
D'Adamio S; Massaro A; Biocca S; Bianchi L; Talamonti M; Galluzzo M
Clin Exp Dermatol; 2020 Aug; 45(6):809-810. PubMed ID: 32472943
[No Abstract] [Full Text] [Related]
16. Superimposed linear atopic dermatitis treated with dupilumab.
Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
[TBL] [Abstract][Full Text] [Related]
19. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab for atopic dermatitis.
Pediatr Dermatol; 2021 Nov; 38(6):1559-1560. PubMed ID: 34931365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
